PaulBrentFerrellJr.MD

PubMed

• 16 citations
  Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase.
  Benjamin J. Reisman, Hui Guo, Haley E. Ramsey, Madison T. Wright, Bradley I. Reinfeld, P. Brent Ferrell, Gary A. Sulikowski, W. Kimryn Rathmell, Michael R. Savona, Lar...> ;Nature Chemical Biology. 2021 Dec 2
• 3 citations
  Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute myeloid leukemia.
  Kathryn I. Sunthankar, Matthew T. Jenkins, Candace H. Cote, Sweta B. Patel, Robert S. Welner, P. Brent Ferrell> ;Leukemia. 2021 Dec 2
• 2 citations
  Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation.
  Haley E. Ramsey, Kristy R. Stengel, James C. Pino, Gretchen Johnston, Merrida A Childress, Agnieszka E. Gorska, Pia Arrate, Londa Fuller, Matthew T. Villaume, Melissa ...> ;Targeted Oncology. 2021 Jul 29
• 18 citations
  Metabolic alterations mediated by STAT3 promotes drug persistence in CML.
  Sweta B. Patel, Travis Nemkov, Davide Stefanoni, Gloria A. Benavides, Mahmoud A. Bassal, Brittany L. Crown, Victoria R. Matkins, Virginia Camacho, Valeriya Kuznetsova,...> ;Leukemia. 2021 Jun 12
• 1 citations
  Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute my...
  Adrianne Rasche, Emily F Mason, Stephen A. Strickland, Michael Byrne, P. Brent Ferrell> ;British Journal of Haematology. 2021 Jun 7
• 2 citations
  A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML.
  Emily F Mason, Olga Pozdnyakova, Mikhail Roshal, Amir T. Fathi, Eytan M. Stein, P. Brent Ferrell, Aaron C. Shaver, Mark G. Frattini, Hongfang Wang, Lei Hua, Jimmy Mu, ...> ;Blood Advances. 2021 Apr 27
• 1 citations
  The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib
  Matthew T. Villaume, M. Pia Arrate, Haley E. Ramsey, Kathryn I. Sunthankar, Matthew T. Jenkins, Tamara K. Moyo, Brianna N Smith, Melissa A. Fischer, Merrida A Childres...> ;Experimental Hematology. 2021 Feb 19
• 18 citations
  Bone marrow Tregs mediate stromal cell function and support hematopoiesis via IL-10.
  Virginia Camacho, Victoria R. Matkins, Sweta B. Patel, Jeremie M. Lever, Zhengqin Yang, Li Ying, Ashley E. Landuyt, Emma C. Dean, James F. George, Henry Yang, Paul Bre...> ;JCI Insight. 2020 Nov 19
• 39 citations
  The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.
  Michael Byrne, Nathalie Danielson, Salyka Sengsayadeth, Adrianne Rasche, Katie Culos, Katie S. Gatwood, Houston Wyatt, Wichai Chinratanalab, Bhagirathbhai Dholaria, P....> ;American Journal of Hematology. 2020 Jun 15
• 34 citations
  Alterations of T-cell-mediated immunity in acute myeloid leukemia.
  Zhuoyan Li, Mary Philip, P. Brent Ferrell> ;Oncogene. 2020 Mar 3
• 90 citations
  Hematologic Complications of Immune Checkpoint Inhibitors
  Elizabeth J. Davis, Joe-Elie Salem, Arissa Young, Jennifer R. Green, P. Brent Ferrell, Kristin K. Ancell, Bénédicte Lebrun-Vignes, Javid Moslehi, Douglas B. Johnson> ;The Oncologist. 2019 May 1
• 24 citations
  Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types
  Allison R. Greenplate, Daniel D. McClanahan, Brian K Oberholtzer, Deon B. Doxie, Caroline E. Roe, Kirsten E. Diggins, Nalin Leelatian, Megan L. Rasmussen, Mark C. Kell...> ;Cancer Immunology Research. 2019 Jan 1
• 100 citations
  Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.
  Douglas B. Johnson, Mellissa J. Nixon, Yu Wang, Daniel Y. Wang, Emily Castellanos, Monica V. Estrada, Paula I. Ericsson-Gonzalez, Candace H Cote, Roberto Salgado, Viol...> ;JCI Insight. 2018 Dec 20
• 28 citations
  Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.
  Kathryn S. Ivy, P. Brent Ferrell> ;Current Hematologic Malignancy Reports. 2018 Aug 1
• 9 citations
  Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
  Stephen A. Strickland, Aaron C. Shaver, Michael Byrne, Robert D. Daber, P. Brent Ferrell, David R. Head, Sanjay R. Mohan, Claudio A. Mosse, Tamara K. Moyo, Thomas Stri...> ;Leukemia Research. 2018 Feb 1
• 27 citations
  Discovery of human cell selective effector molecules using single cell multiplexed activity metabolomics
  David C. Earl, P. Brent Ferrell, Nalin Leelatian, Jordan Froese, Benjamin J. Reisman, Jonathan M. Irish, Brian O. Bachmann> ;Nature Communications. 2018 Jan 2
• 64 citations
  Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow.
  Mikael Roussel, P. Brent Ferrell, Allison R. Greenplate, Faustine Lhomme, Simon Le Gallou, Kirsten E. Diggins, Douglas B. Johnson, Jonathan M. Irish> ;Journal of Leukocyte Biology. 2017 Aug 1
• 30 citations
  Systems immune monitoring in cancer therapy.
  Allison R. Greenplate, Douglas B. Johnson, P. Brent Ferrell, Jonathan M. Irish> ;European Journal of Cancer. 2016 Jul 1
• 16 citations
  Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti–PD-1 Therapy
  Allison R. Greenplate, Douglas B. Johnson, Mikael Roussel, Michael R. Savona, Jeffrey A. Sosman, Igor Puzanov, P. Brent Ferrell, Jonathan M. Irish> ;Cancer Immunology Research. 2016 Mar 10
• 105 citations
  Methods for discovery and characterization of cell subsets in high dimensional mass cytometry data.
  Kirsten E. Diggins, P. Brent Ferrell, Jonathan M. Irish> ;Methods. 2015 Jul 1
• 259 citations
  Carbamazepine, HLA-B*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations
  P. Brent Ferrell, Howard L. McLeod> ;Pharmacogenomics. 2008 Oct 14
• Join now to see all

Lectures

• FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• IDH2 Mutations Induce Altered STAT Signaling and Cytokine Responses Which Are Restored By Enasidenib 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018